Trial Profile
A phase II study of TAS-102 plus Bevacizumab therapy for advanced/recurrent colorectal cancer with difficulty on intensive chemotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2019
Price :
$35
*
At a glance
- Drugs Tipiracil/trifluridine (Primary) ; Bevacizumab
- Indications Colorectal cancer
- Focus Therapeutic Use
- 27 Aug 2019 Status changed from recruiting to discontinued.
- 21 Jun 2016 New trial record